Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1
Launched by HOSPITAL UNIVERSITÁRIO PROFESSOR EDGARD SANTOS · Sep 25, 2024
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
Subjects presenting OAB according to ICS, associated with the HTLV-1 infection were invited by the investigators to participate in the study according inclusion criteria . Participants who accepted were randomly allocated to two groups (G1 and G2) by the free randomization website. Group 1 was treated with Darifenacin, and group 2 with the PTENS protocol.
Drug Treatment Protocol:
The anticholinergic Fenazic (Adium) was used in a single dose of 15mg/day for 2 months.
PTENS Protocol:
The treatment consisted of PTENS with the Neurodyn Portable TENS FES(21) neuromuscular stimulation device ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HTLV-1 infection
- • Overactive bladder symptom
- • 18 years of age or older
- Exclusion Criteria:
- • HTLV-1 infected subjects with HAM
- • Stroke
- • Parkinson
- • HIV infection
- • Prostatic hyperplasia
- • Pacemaker use
- • Genitourinary tract infection
- • Glaucoma
About Hospital Universitário Professor Edgard Santos
Hospital Universitário Professor Edgard Santos (HUPE) is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and patient care. Affiliated with the Federal University of Bahia, HUPE integrates education, research, and clinical practice, fostering a multidisciplinary approach to health sciences. The hospital conducts a wide range of clinical trials aimed at improving treatment outcomes and contributing to the scientific community. With a commitment to excellence and patient-centered care, HUPE plays a pivotal role in translating research findings into practical applications that enhance health and well-being in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salvador, Ba, Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported